Therapy and management of frontal lobe dementia patients

Neurology

Volumn 56, Issue 11 SUPPL. 4, 2001, Pages

  Litvan, I ^a  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUOXETINE; FLUVOXAMINE; NEUROTRANSMITTER; PAROXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAU PROTEIN;

APATHY; ARTICLE; CAREGIVER; CHROMOSOME 17; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DEMENTIA; FRONTAL LOBE DEMENTIA; FRONTOTEMPORAL DEMENTIA; HALLUCINATION; HISTOPATHOLOGY; HUMAN; MOTOR DYSFUNCTION; PARKINSONISM; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL SUPPORT; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

EID: 0034978405     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.56.suppl_4.s41     Document Type: Article

References (55)

1. Clinical and neuropathological criteria for frontotemporal dementia
2. Alzheimer disease and frontotemporal dementias
3. Pick complex and Pick's disease: The nosology of frontal lobe dementia, primary progressive aphasia, and corticobasal ganglionic degeneration
4. What are the obstacles for an accurate diagnosis of Pick's disease? A clinicopathologic study
5. Predictors of institutionalization among caregivers of patients with Alzheimer's disease
6. An intervention that delays institutionalization of Alzheimer's disease patients: Treatment of spouse-caregivers
7. The caregiver's role in Alzheimer's disease
8. Pick's disease versus Alzheimer's disease: A comparison of clinical characteristics
9. Altered serotonergic and cholinergic synaptic markers in Pick's disease
10. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy
11. Neurochemical and histopathologic alterations characteristic of Pick's disease in a non-demented individual
12. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence
13. The elderly depressed and treatment with fluvoxamine
14. Hyperphagia in dementia: Fluvoxamine takes the biscuit
15. Apathy and indifference in patients on fluvoxamine and fluoxetine
16. Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors
17. Serotonin and depression in frontal lobe dementia
18. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease
19. Pathophysiology of the serotonin syndrome
20. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment
21. Efficacy and safety of sertraline treatment of posttraumatic stress disorder
22. Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: Preliminary results
23. Bromocriptine treatment for perseveration in demented patients
24. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients
25. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration
26. Somatostatin and neuropeptide Y in cerebrospinal fluid: Correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia
27. Tau protein pathology in neurodegenerative diseases
28. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
29. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17
30. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements
31. Free radical formation in autopsy samples of Alzheimer and control cortex
32. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders
33. Lentiviral gene transfer to the nonhuman primate brain
34. Life events as correlates of burden in spouse caregivers of persons with Alzheimer's disease
35. Stress, social support, and psychological distress of family caregivers of the elderly
36. Depressive symptomatology in first-degree family caregivers of Alzheimer disease patients: A cross-ethnic comparison
37. Social and depressive stress suffered by spouses of patients with mild dementia
38. The stress and psychological morbidity of the Alzheimer patient caregiver
39. Caregiver stress: A failed negotiation? A qualitative study in South West France
40. Patterns of burden in wives who care for husbands with dementia
41. Participation in clinical trials and long-term outcomes in Alzheimer's disease
42. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health
43. Age-related changes in cardiovascular response as a function of a chronic stressor and social support
44. Stress-related impairments in cellular immunity
45. Chronic stress and immunity in family caregivers of Alzheimer's disease victims
46. Stress-related immune suppression: Health implications
47. The influence of psychological stress on the immune response to vaccines
48. Chronic caregiving stress alters peripheral blood immune parameters: The role of age and severity of stress
49. Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination
50. Chronic stress associated with spousal caregiving of patients with Alzheimer's dementia is associated with downregulation of B-lymphocyte GH mRNA
51. Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids
52. Cognitive-behavioral intervention for homebound caregivers of persons with dementia
53. Psychosocial modulation of cytokine-induced natural killer cell activity in older adults
54. Chronic stress, social support, and persistent alterations in the natural killer cell response to cytokines in older adults
55. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: Results from the MALT clinical trial